Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence‐based international consensus
Alimentary Pharmacology & Therapeutics2018Vol. 47(8), pp. 1054–1070
Citations Over TimeTop 1% of 2018 papers
A. P. S. Hungin, Catherine Mitchell, Peter J. Whorwell, Catherine Mulligan, O. Jackson Cole, Lars Agréus, Pierluigi Fracasso, Christos Lionis, Juan Manuel Mendive, J Foy, Bohumil Seifert, Knut‐Arne Wensaas, Christopher Winchester, N. de Wit, the European Society for Primary Care Gastroenterology
Abstract
This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publications did not report benefits of probiotics, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety. This study will help clinicians recommend/prescribe probiotics for specific symptoms.
Related Papers
- → Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case–control study in irritable bowel syndrome(2005)183 cited
- Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study.(2008)
- → Su1194 - Efficacy of Rifaximin in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Prior use of IBS Medications(2018)1 cited
- → Mo1329 RIFAXIMIN IS EFFICACIOUS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS PREVIOUSLY TREATED WITH OTHER IBS MEDICATIONS(2020)
- → Fr256 RIFAXIMIN SIGNIFICANTLY IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA: A POOLED ANALYSIS OF THREE PHASE 3 TRIALS(2021)